

<!-- page 1 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
1A
w;s úfYI
wxl 1913$7 - 2015 uehs ui 05 jeks wÕyrejdod - 2015'05'05
No. 1913/7  - TUESDAY, MAY  05,  2015
EXTRAORDINARY
Y%S ,xld m%cd;dka;%sl iudcjd§ ckrcfha .eiÜ m;%h
The Gazette of the Democratic Socialist Republic of Sri Lanka
(Published by Authority)
PART I : SECTION (I) — GENERAL
Government  Notifications
This Gazette Extraordinary can be downloaded from www.documents.gov.lk
                  
       
              
               
            
        
                  
     
         
             
         
               
            
               
               
            
               
        
                 
        
              
               
            
         
                  
CONVENSION   AGAINST  DOPING  IN   SPORT  ACT,   No. 33   OF  2013
REGULA TIONS made by the Minister of  Sports under Section 34 read with Section 3 of the Convention against Doping in
Sport Act, No. 33 of 2013.
NAVIN DISSANAYAKE,
Minister of Tourism and Sports.
Colombo,
29th April, 2015.
Regulations
1. These regulations may be cited as the Anti-Doping (Prohibited List) Regulations  No. 01 of 2015.
2. These regulations shall be deemed to have come into  operation on January 1st, 2015.
THE  WORLD  ANTI-DOPING  CODE
THE 2015 PROHIBITED LIST INTERNATIONAL STANDARD
The Official text of the Prohibited List shall be maintained by W ADA and shall be published in English and French.
In the event of any conflict between the English and French versions,  the English  version shall prevail.
This List shall come into effect on 01st  January 2015.
The 2015 prohibited List
20th September 2014
3 – PG 2453

<!-- page 2 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
2A
THE    2015    PROHIBITED    LIST   WORLD    ANTI-DOPING    CODE
Valid  01st January 2015
IN accordance with Article  4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall  be considered  as “Specified
Substances” except Substances in classes S1, S2, S4.4,  S4.5, S6.a, and Prohibited Methods  M1, M2 and M3.
SUBSTANCES    AND    METHODS    PROHIBITED    AT    ALL   TIMES
(IN-AND  OUT-OF-COMPETITION)
PROHIBITED    SUBSTANCES
SO. NON-APPROVED   SUBSTANCES
Any pharmacological substance which is not addressed  by any of the subsequent sections of the List and with no current
approval by any governmental  regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or cinical
developement or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.
S1.   ANABOLIC   AGENTS
Anabolic agents are prohibited.
1.Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS including:
1- androstenediol 
(5α-androst-1-ene-3β,17β-diol); 1-androstenedione (5α-androst-1-ene-3, 17-dione);  bolandiol (estr-4-ene-3β,17β-
diol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-
4-en-20-yn-17 α-ol); dehydrochlormethyltestosterone (4-chloro- 17β -hydroxy- 17α -methylandrosta-1,4-dien-3-one);
desoxymethyltestosterone  ( 17α-methyl-5 α-androst-2,-en- 17β-ol); drostanolone  ; ethylestrenol  (19-norpregna-4-en- 17α-ol);
fluoxymesterone;  formebolone; furazabol  ( 17α-methyl[1,2,5]oxadiozolo[3',4':2,3]-5 α-androstan- 17β-ol); gestrionone ;  4-
hydroxytestosterone   ( 4,17β -dihydroxyandrost-4-en- 3-one); mestanolone,mestarolone, metandienone ; ( 17β-hydroxy-17 α-
methylandrosta-1,4-dien-3-one); metenolone; methandriol; methasterone  ( 17β-hydroxy-2 α,17α-dimethyl-5 α-androstan-3-one);
methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one);  Methyl-1-testosterone ( 17β-hydroxy-17α,methyl-5α-androst-1-en-
3-one); methylnortestosterone  ( 17β-hydroxy-17α,methylestr-4-methyl-1-1testasterone (17 β − hydroxy-17α-methyl-5α−androst-1-en-
3-one) ; methylnortestosterone 17 β-hyaroxy-17α - methylester-4-en-3-one); methyltestosterone; metribolone (methyltrienolone,17β-
hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone;  nandrolone; 19 norandrostenedione  (estr-4-ene-3,17-dione) norboletone
norclostebol norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-
1'H-pyrazolo[3,4:2,3]-5 α-androstane); quinbolone; stanozolol; stenbolone -1-testosterone  ( 17β-hydroxy-5 α-androst-1-en-3-one);
tetrahydrogestrinone; (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one); trenbolone  (17β-hydroxyestr-4,9,11-trien-3-one);
and  other substances with a similar chemical structure or similar biological effect (s).
b. Endogenous** AAS when administered exogenously :
Androstenediol (androst-5-ene-3β,17β-diol);  androstenedione, (androst-4-ene-3,17-dione);  dihydrotestosterone; (17β-hydroxy-5α-
androstan-3-one);  prasterone (dehydroepiandrosterone,DHEA,3 β-hydroxyandrost-5-en-17-one)  testosterone; and their metabolites
and  isomers, including but not limited to:
5α-androstane- 3α3α3α3α3α-17α17α17α17α17α-diol; 5α5α5α5α5α-androstane-3 ααααα-17βββββ-diol; 5 α 5 α 5 α 5 α 5 α-androstane-3 βββββ-17ααααα-diol; 5 ααααα-androstane- 3β3β3β3β3β-17β17β17β17β17β-diol;  5 βββββ-
androstane-3α-17β-diol;- androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol;
androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17β-diol; 4-androstendiol (androst-
4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3, 17-dione) ; androsterone (3β-hydroxy-5α-androstan-17-one) ; epi-
dihydrotestrosterone ; epitestostereone ; etiocholanolone ; 7α - hydorxy-DHEA ; 7β- hyroxy-DHEA ; 7-keto-DHEA ; 19-
norandrosterone ; 19-noretiocholanolone.

<!-- page 3 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
3A
   2. OTHER   ANABOLIC   AGENTS
Including, but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs; e.g. andarine and ostarine), tibolone, zeranol and zilpaterol.
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily  produced by the body naturally.
** “endogenous” refers to a substance which is  ordinarily  produced by the body naturally.
S2. PEPTIDE  HORMONES,   GROWTH     FACTORS,   RELATED    SUBSTANCES AND   MIMETICS
The following substances, and other substances with similar chemical structure or similar  biological effect(s), are
prohibited:
1. Erythropoietin - Receptor agonists:
1.1 Erythropoiesis-Stimulating Agents (ESAs)  including e.g. darbepoietin (dEPO);  erythropoietius (EPO);EPO-
Fc; EPO mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; and methoxy polyethylene glycol-epoetin
beta (CERA)
1.2 Non - erythropoietic EPO - Receptor agonists, e.g. ARA - 290, asialo EPO and carbamylated EPO;
2. Hypoxia - inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon;
3. Chorionic Gonadotrophin (CG) and Luteinizing  Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin
and triptorelin, in males;
4. Corticotrophins and their releasing factors, e. g. corticorelin ;
5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its
analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and
ghrelin mimetics,  e.g. anamorelin and ipamorelin; and GH - Releasing Peptides  (GHRPs) e.g. alexamorelin,
GHRP - 6, hexarelin and pralmorelin (GHRP - 2).
Additional prohibited growth factors:
Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor - 1 (IGF-1)  and
its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial
Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/
degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
S3. BETA - 2 AGONISTS
All beta - 2 agonists, including all optical isomers, e.g. d - and l- where relevant, are prohibited.
Except :
* Inhaled salbutamol (maximum 1600 micrograms over 24 hours)
* Inhaled formoterol (maximum delivered dose 54  micrograms over 24 hours); and
* Inhaled salmeterol  in accordance with the manufacturers’ recommended therapeutic regimen.
The presence in urine of salbutamol in excess of 1000 ng/ml- or formoterol in excess of 40ng/ml- is presumed not to be an
intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete
proves, through  a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the
therapeutic inhaled dose up to the maximum indicated above.

<!-- page 4 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
4A
S4.   HORMONE   AND   METABOLIC   MODULATORS
The following hormones and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to: aminoglutethimide; anastrozole; androsta - 1,4,6-triene-3,
17-dione (androstatrienedione); 4- androstene-3,6,17 trione (6-oxo); exemestane; formestane; letrozole and
testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to : raloxifene; tamoxifen and to emifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene; cyclofenil and fulvestrant.
4. Agents modifying myostatin function (s) including, but not limited, to : myostatin inhibitors.
5. Metabolic  modulators:
5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated
Receptor∂ (PPAR∂)  agonists, e.g. GW 1516;
5.2 Insulins;
5.3 Trimetazidine ;
S5. DIURETICS    AND   MASKING    AGENTS
The following  diuretics, and masking agents are prohibited, as are other substances with a similar chemical structure or
similar biological effect (s).
Including, but not limited to:
Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran,
hydroxyethyl  starch and mannitol.
Acetazolamide; amiloride;  bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide;
metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene
and vaptans, e.g. tolvaptan.
Excpet:
Drospirenone; pamabrom; and topical dorzolamide and brinzolamide.
Local administration of felypressin in dental anaesthesia.
The detection in an Athlete’s Sample at all times or In -Competition, as applicable, of any quantity of the following substances
subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction
with a diuretic or masking agent, will be considered as an Adverse Analytical Finding  unless the Athlete has an approved
TUE for that substance in addition to the one granted for the diuretic or masking agent.

<!-- page 5 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
5A
PROHIBITED   METHODS
M1.  MANIPULATION    OF    BLOOD   AND   BLOOD    COMPONENTS
The following  are prohibited:
1. The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of  oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR 13) and modified  haemoglobin products, e.g. haemoglobin-based blood
substitutes and microencapsulated haemoglobin  products, excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
M2.  CHEMICAL    AND   PHYSICAL    MANI PULATION
The following  are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and  validity of Samples collected during Doping Control.
Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.
2. Intravenous infusions and /or injections of more than 50ml  per 6 hour period except for those legitimately received
in the course of hospital admissions, surgical procedures or clinical investigations.
M3.  GENE    DOPING
The following with the potential to enhance sport performance, are prohibited:
1. The transfer of ploymers of nucleic acids  or nucleic acid analogues;
2. The use of normal or genetically modified cells.
SUBSTANCES   AND    METHODS   PROHIBITED
IN- COMPETITION
In addition to the categories SO to S5 and M1 to M3 defined above,
the following categories are prohibited in - Competition:
PROHIBITED    SUBSTANCES
S6. STIMULANTS
All stimulants, including all optical isomers, e.g. d- and 1- where relevant, are prohibited.
Stimulants include:
(a) Non- Specified Stimulants:

<!-- page 6 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
6A
Adrafinil; amfepramone; amfetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex;
cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4- phenylpiracetam
(carphedon)] ; furfenorex; mefenorex; mephentermine; mesocarb; metamfetamine ( d-) p- methylamphetamine; modafinil;
norfenfluramine; phendimetrazine; phentermine; prenylamine and prolintane.
A stimulant not expressly  listed in this section is specified substance.
b. Specified Stimulants.
Including, but not limited to:
Benzfetamine; cathine**; cathinone and its analogues, e.g. mephedrone, methedrone, and a- pyrrolidinovalerophenone;
dimethylamphetamine; ephedrine ***; epinephrine**** (adrenaline); etamivan; etilamfetamine;  etilefrine; famprofazone;
fenbutrazate; fencamfamin; heptaminol; hydroxyamfetamine (parahydroxyamphetamime); isometheptene; 
levmetamfetamine;
meclofenoxate; methylenedioxymethamphetamine; methylephedrine***;  methylhexaneamine; (dimethylpentylamine);
methylphenidate ; nikethamide , norfenefrine ; octopamine ; oxilofrine  (methylsynephrine) pemoline; penterazol ;
phenethylamine and its derivatives; phenmetrazine; phenpromethamine; propylhexedrine;   pseudoephedrine*****;
selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine), tuaminoheptane;  and other substances
with a similar chemical structure or similar biological effect(s).
Except:
Imidazole derivatives for topical/ophthalmic use and those stimulats included in the 2015 monitoring Program*.
* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine; These substances
are included in the 2015 monitoring Program, and are not considered Prohibited Substances.
** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
*** Ephedrine and methylephedrine:  Prohibited when the concentration of either in urine is greater than 10  micrograms
per milliliter.
**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration
with local anaesthetic agents.
***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.
S7. NARCOTICS
Prohibited:
Buprenorphine; dextromoramide;  diamorphine (heroin); fentanyl and its derivatives; hydromorphone; methadone; morphine;
oxycodone; oxymorphone; pentazocine and pethidine.
S8. CANNABINOIDS
Prohibited:
Natural, e.g. cannabis, hashish and marijuana, or synthetic
   9- tetrahydrocannabinol (THC).
Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210.
S9. GLUCOCORTICOIDS
All glucocorticoids are prohibited when administred by oral, intravenous, intramuscular or rectal routs.

<!-- page 7 -->

I fldgi ( ^I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2015'05'05
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 05.05.2015
7A
SUBSTANCES   PROHIBITED   IN- PARTICULAR
SPORTS
P1. ALCOHOL
Alcohol (ethanol) is prohibited  In-Competition only, in the following sports, Detection will be conducted by analysis of
breath and /or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10g/L.
Air Sports (FAI) Motorcycling (FIM)
Archery (WA) Powerboating (UIM)
Automobile (FIA)
P2. BETA - BLOCKERS
Beta-blockers are prohibited  In-Competition only, in the following sports, and also prohibited Out-of-Competition where
indicated.
Archery (WA)*
Automobile (FIA)
Billiards (all disciplines) (WCBS)
Darts (WDF)
Golf (IGF)
Shooting (ISSF, IPC)*
Skiing/Snowboarding (FIS) in ski Jumping, Freestyle aerials/halfpipe and snowboard halfpipe/big air.
Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight
apnoea.
* Also proibited Out-of-Competition
Including, but not limited to :
Acebutolol; alprenolol; atenolol; betaxolol; bisoprolol; bunolol; carteolol; carvedilol; celiprolol; esmolol; labetalol;
levobunolol; metipranolol; metoprolol; nadolol; oxprenolol; pindolol; propranolol; sotalol and timolol.
WORLD
ANTI -DOPING
AGENCY
THE  2015 MONITORING  PROGRAM *
The following substances are placed on the 2015 Monitoring Program:
1. Stimulants: In-Competition only: Bupropion, caffeine, nicotine,  phenylephrine, phenylpropanolamine,
Pipradrol and synephrine.
2. Narcotics: In-Competition only: Hydrocodone, mitragynine, morphine/codeine ratio, tapentadol and
tramadol
3. Glucocorticoids: In-Competition (by routes of administration other than oral, intravenous, intramuscular or
rectal)  and out-of-Competition (all routes of admimistration)
4. Telmisartan: In-and out -of -Competition
5. Meldonium: In- and out- of -Competition
* The world Anti-Doping Code (Article 4.5) states : “WADA  in consultation with Signatories and governments, shall
establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to
monitor in order to detect patterns of misuse in sport.”
05- 451
PRINTED AT THE DEPARTMENT  OF GOVERNMENT PRINTING , SRI LANKA.